Intravenous tranexamic acid (TXA) has been shown to be effective in reducing blood loss and the need for transfusion after joint replacement. Recently, there has been interest in applying it topically before the closure of surgical wounds. This has the advantages of ease of application, maximum concentration at the site of bleeding, minimising its systemic absorption and, consequently, concerns about possible side-effects.

We conducted a systematic review and meta-analysis which included 14 randomised controlled trials (11 in knee replacement, two in hip replacement and one in both) which investigated the effect of topical TXA on blood loss and rates of transfusion. Topical TXA significantly reduced the rate of blood transfusion (total knee replacement: risk ratio (RR) 4.51; 95% confidence interval (CI): 3.02 to 6.72; p < 0.001 (nine trials, I² = 0%); total hip replacement: RR 2.56; 95% CI: 1.32 to 4.97, p = 0.004 (one trial)). The rate of thromboembolic events with topical TXA were similar to those found with a placebo. Indirect comparison of placebo-controlled trials of topical and intravenous TXA indicates that topical administration is superior to the intravenous route.

In conclusion, topical TXA is an effective and safe method of reducing the need for blood transfusion after total knee and hip replacement. Further research is required to find its optimum dose for topical use.

Cite this article: Bone Joint J 2014;96-B:1005–15.

Introduction

Wound surveillance has been reported to result in a significant fall in the incidence of wound sepsis in total knee arthroplasty (TKA). However, there is currently little guidance on the definition of surgical wound infection that is best to be used for surveillance. The purpose of this study was to assess the agreement between three common definitions of surgical wound infection as a performance indicator in TKA; (a) the CDC 1992 definition, (b) the NINSS modification of the CDC definition and (c) the ASEPSIS scoring method applied to the same series of surgical wounds.

Introduction

Up to 2% of total hip arthroplasties (THA) are still complicated by infection. This leads to dissatisfied patients with poor function, and has far-reaching social and economic consequences. The challenge in these cases is the eradication of infection, the restoration of full function and the prevention of recurrence. We report the outcome of early aggressive debridement in the acutely infected THA.

Introduction

Total knee replacements (TKR) are among the commonest operations performed in orthopaedic practice. Literature review showed that 10-30% of patients who underwent TKR needed 1-3 units of blood.

Tranexamic acid (TXA) has been popularised as an effective way to reduce blood loss and subsequent blood transfusion.

Our aim was to investigate the value of TXA in reducing blood loss and blood transfusion after TKR and other clinical outcomes such as deep venous thrombosis (DVT), pulmonary embolism (PE), ischaemic heart diseases and mortality.

Objectives

To investigate the value of tranexamic acid (TA) in reducing blood loss and blood transfusion after TKR and other clinical outcomes such as deep venous thrombosis (DVT), pulmonary embolism (PE), ischaemic heart diseases and mortality.

Introduction

Up to 2% of total knee arthroplasties (TKA) are still complicated by infection. This leads to dissatisfied patients with poor function, and has far-reaching social and economic consequences. The challenge in these cases is the eradication of infection, the restoration of full function and the prevention of recurrence.

We report the outcome of prosthesis sparing early aggressive debridement in the acutely infected TKA.

We conducted a systematic review and meta-analysis of randomised controlled trials evaluating the effect of tranexamic acid (TXA) upon blood loss and transfusion in primary total knee replacement. The review used the generic evaluation tool designed by the Cochrane Bone, Joint and Muscle Trauma Group. A total of 19 trials were eligible: 18 used intravenous administration, one also evaluated oral dosing and one trial evaluated topical use. TXA led to a significant reduction in the proportion of patients requiring blood transfusion (risk ratio (RR) 2.56, 95% confidence interval (CI) 2.1 to 3.1, p < 0.001; heterogeneity I² = 75%; 14 trials, 824 patients). Using TXA also reduced total blood loss by a mean of 591 ml (95% CI 536 to 647, p < 0.001; I² = 78%; nine trials, 763 patients). The clinical interpretation of these findings is limited by substantial heterogeneity. However, subgroup analysis of high-dose (> 4 g) TXA showed a plausible consistent reduction in blood transfusion requirements (RR 5.33; 95% CI 2.44 to 11.65, p < 0.001; I² = 0%), a finding that should be confirmed by a further well-designed trial. The current evidence from trials does not support an increased risk of deep-vein thrombosis (13 trials, 801 patients) or pulmonary embolism (18 trials, 971 patients) due to TXA administration.

Background: Total hip replacement (THR) is one of the commonest operations in orthopaedic practice.

Literature review showed that 20–70% of patients who underwent THR needed 1–3 units of blood. Although safer than ever, allogeneic transfusion is still associated with risks for the recipient. There has been unsettled search for ways to reduce such blood loss and transfusion.

Tranexamic acid has been popularised as an effective way to reduce blood loss and subsequent blood transfusion.

Objectives: To investigate the value of Tranexamic acid in reducing blood loss and blood transfusion after THR and other clinical outcomes such as deep venous thrombosis (DVT), pulmonary embolism (PE), ischaemic heart diseases and mortality.

Patients and Methods: A systematic review and meta-analysis of published randomised and quasi-randomised trials which used tranexamic acid to reduce blood loss in hip arthroplasty was conducted. The data was evaluated using the generic evaluation tool designed by the Cochrane Bone, Joint and Muscle Trauma Group.

Results:

Blood loss

Seven studies (250 patients) were eligible for this outcome. Using Tranexamic acid reduced blood loss by an average of 155 ml (P-value < 0.00001, 95% CI (87–224), Heterogeneity I2 69 %.)

Blood transfusion

Nine studies (463 patients) were eligible for this outcome. Tranexamic acid led to a reduction in the proportion of patients requiring blood transfusion (Odds Ratio of 0.35, P- value < 0.00001, 95% CI (0.22–0.55), Heterogeneity I2 25 %.)

Other outcomes

There were no significant differences in the length of stay, DVT, PE, mortality, wound haematoma or infections between the study groups.

Conclusion: The use of Tranexamic acid in THR results in significant reduction of blood loss and blood transfusion.

Introduction: Ankle fractures are among the commonest orthopaedic injuries. A delay in operating is often due to the swelling associated with such fractures. On the other hand, the delay in operative fixation beyond 24 h from injury is associated with a lengthening of hospital stay which costs approximately £225 per patient per day for an acute trauma bed.

Objectives: The aim of this study was to analyse the relationship between the delay in surgical intervention of open reduction and internal fixation of ankle fractures from presentation due to ankle swelling, and the length of hospital stay and postoperative complications.

Patients and Methods: A retrospective study of 145 consecutive patients treated for ankle fractures over a period of 12 months between January and December 2008. results were collated excluding talar and pilon fractures. Emergency department presentation times were noted and time of anaesthetic to determine surgical delay. Notes were reviewed for inpatient stay and postoperative complications.

Results: There were 62 male and 83 female patients with a mean age of 49 years. In total, 117 (80%) patients were operated on within 24 hours of presentation (early group). 28 patients’ surgery was delayed beyond 24 hours (delayed group). Of the 117 patients the mean inpatient stay was 3.79 days (± 2.39) whereas in the delayed group the mean stay was 8.57 days (± 6.54). Of the delayed group, 57% of the cases had swelling as the cause of a postponed operation, whereas other causes included lack of theatre time and lack of fitness for surgery. In the early group, 5 patients (4.27%) had wound infections and one patient had a chest infection (0.85%). Four patients (14.28%) from the delayed group developed wound infections all of whom were from patients with ankle swelling.

Conclusion: We recommend that policies be put in place to provide early operative intervention for patients with fractured ankles prior to the development of swelling as this would result in improved patient outcome and significant financial savings. If an operation is not feasible within 24 hours of admission and the ankle is swollen resulting in a high operative risk, we recommend sending the patient home for a period of 5–7 days with advice on RICE and anticoagulation which would both permit surgery and cut down costs.

Introduction: Up to 2% of total knee arthroplasties (TKA) are still complicated by infection. This leads to dissatisfied patients with poor function, and has far-reaching social and economic consequences. The challenge in these cases is the eradication of infection, the restoration of full function and the prevention of recurrence. We report the outcome of prosthesis sparing early aggressive debridement in the acutely infected TKA.

Methods: We studied 29 consecutive patients referred with acutely infected TKA (18 primaries, 11 revisions) which occurred within 6 weeks of the index operation or of haematogenous spread. Microbiology confirmed bacterial colonization in all cases with 20 early postoperative infections and 9 cases of acute haematogenous spread. All patients underwent aggressive open debridement, a thorough synovectomy and a change of insert. Antibiotics were continued until inflammatory markers and the plasma albumin concentration returned to within normal limits.

Results: Three patients required multiple washouts. 8 patients needed a two stage revision. 21 patients returned to their expected functional level without removal of the implants and with no radiographic evidence of prosthetic failure. At a minimum 2 years follow-up, we had a 72% infection control rate. The outcome was significantly better in patients treated in the first 120 hours after presentation.

Discussion and Conclusion: Our data suggests that there is a role for early aggressive open debridement in acute infections after TKA with an excellent chance of prosthesis salvage.

We report a systematic review and meta-analysis of published randomised controlled trials evaluating the efficacy of tranexamic acid (TXA) in reducing blood loss and transfusion in total hip replacement (THR). The data were evaluated using the generic evaluation tool designed by the Cochrane Bone, Joint and Muscle Trauma Group. We identified 11 clinical trials which were suitable for detailed extraction of data. There were no trials that used TXA in revision THR. A total of seven studies (comprising 350 patients) were eligible for the blood loss outcome data. The use of TXA reduced intra-operative blood loss by a mean of 104 ml (95% confidence interval (CI) −164 to −44, p = 0.0006, heterogeneity I² 0%), postoperative blood loss by a mean of 172 ml (95% CI −263 to −81, p = 0.0002, heterogeneity I² 63%) and total blood loss by a mean of 289 ml (95% CI −440 to −138, p < 0.0002, heterogeneity I² 54%).

TXA led to a significant reduction in the proportion of patients requiring allogeneic blood transfusion (risk difference −0.20, 95% CI −0.29 to −0.11, p < 0.00001, I² 15%). There were no significant differences in deep-vein thrombosis, pulmonary embolism, infection rates or other complications among the study groups.

Since the era of total knee replacement (TKR) began in the late 1960s, total knee replacement has become one of the commonest operations in orthopaedic practice.

TKR is frequently associated with transfusion of allogenic blood Benoni G 1995; Seppo T 1997. In our centre, 30 % of patients who had undergone TKR received allogenc blood transfusion perioperatively. Although, serological screening has reduced the risk for viral infection to a very low levelKlein HG 1995; Schreiber GB 1996, the public is still concerned about this potential serious complication. Allogenic blood transfusion can be also associated with other non infectious complications such as haemolysis, immunosuppression, transfusion-related acute lung injury and even death.Madjdpour C 2005 Therefore, further refinement of strategies to avoid exposure to allogeneic blood is needed.

Amongst the technologies to minimise the need for blood transfusion is the use of the anti-fibrinolytic drugs aprotinin, tranexamic acid (TXA), and epsilon amino-caproic acid (EACA).New Reference

Objectives: The purpose of this review is to investigate the evidence for the efficacy of Tranexamic acid in reducing peri-operative blood loss and blood transfusion after total knee replacement, and the evidence for any effect on clinical outcomes such as reduction in re-operation rates or increase in complication rates (e.g. deep venous thrombosis, pulmonary embolism, ischaemic heart diseases and mortality).

Method: Systematic review and metananalysis based on Cochrane guidelines of all randomised and quasirandomised trials.

Results: Fiften RCTs were included in the study; there has been a significant reduction of blood loss (P value 0.00001, I2 = 89%), blood transfusion without increase in systeanatic side effects such as ischaemic heart diseases, DVT, pulmondary embolisms. There was no singnificant difference in length of stay.